Pattern of drug resistance among patients who fail Cat II regimen and patients who fail standard treatment: is there any difference? Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006
Chinese subgroup results from a study comparing single-inhaler triple therapy with dual therapy in COPD Source: International Congress 2017 – COPD management Year: 2017
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001
Frequency of drug resistance and treatment results with standard chemotherapeutical regimen in patients with newly detected tuberculosis on the data of district hospital, Kiev Source: Eur Respir J 2002; 20: Suppl. 38, 548s Year: 2002
Frequency of drug resistance and treatment results in patients with newly detected tuberculosis using standard chemotherapeutical regimen on the data of district hospital, Kiev Source: Eur Respir J 2002; 20: Suppl. 38, 402s Year: 2002
Comparing different initial doses of afatinib used as first-line treatment for patients with stage IV lung adenocarcinoma Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017
Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses Source: ERJ Open Res, 4 (2) 00119-2017; 10.1183/23120541.00119-2017 Year: 2018
A study of the effectiveness of individual components of pulmonary rehabilitation when compared with the combined programme and standard treatment Source: Eur Respir J 2004; 24: Suppl. 48, 209s Year: 2004
Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population? Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021
Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001
Patient selection? One fits all (monotherapy versus combined therapy)? Source: Sleep and Breathing Conference 2021 Year: 2021
A preliminary study comparing pemetrexed/carboplatin (PC) versus docetaxel/carboplatin (DC) as second line therapy in lung cancer patients Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009
Comparison of the efficacy of two methods of treatment, standard and modified, on patients with Isoniazid resistant tuberculosis Source: Annual Congress 2007 - Difficult tuberculosis cases II Year: 2007
Three drug regimen in SCLC-ED patients: a phase II study Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007
Comparison of initial drug treatment of incident COPD patients with German treatment guidelines Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data Year: 2021
Faster clinical improvement and earlier discharge from hospital in CAP patients under sequential moxifloxacin treatment compared to standard therapy Source: Eur Respir J 2004; 24: Suppl. 48, 188s Year: 2004
Tolerability and efficacy of budesonide/formoterol via Turbuhaler® vs standard treatment in Japanese patients with moderate to severe COPD: 52-week phase III study results Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012